Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Cambridge Biotech urine HIV test

This article was originally published in The Gray Sheet

Executive Summary

Cambridge Biotech urine HIV test: Cambridge Biotech's HIV-1 Western Blot confirmatory test for use with urine samples is approvable. A product license application supplement can be approved upon FDA sign-off on final labeling. The kit will be offered as the confirmatory test for the Calypte HIV-1 Urine EIA screening test, which FDA approved in August 1996 ("The Gray Sheet" Aug. 12, 1996, p. 3). Under an agreement between Calypte Biomedical and Cambridge Biotech, Calypte was responsible for collecting the data to support Cambridge Biotech's PLA supplement. In June 1996, FDA's Blood Products Advisory Committee concluded the test needed more data to demonstrate its effectiveness ("The Gray Sheet" July 1, 1996, p. 12)...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT008789

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel